Journal
CURRENT ISSUES IN MOLECULAR BIOLOGY
Volume 43, Issue 3, Pages 1451-1459Publisher
MDPI
DOI: 10.3390/cimb43030102
Keywords
azithromycin; mineralized nodule; osteoblast; osteopontin
Categories
Ask authors/readers for more resources
This study found that high concentrations of azithromycin suppress osteogenic function in osteoblastic cells, while low concentrations have no effect.
Azithromycin displays immunomodulatory and anti-inflammatory effects in addition to broad-spectrum antimicrobial activity and is used to treat inflammatory diseases, including respiratory and odontogenic infections. Few studies have reported the effect of azithromycin therapy on bone remodeling processes. The aim of this study was to examine the effects of azithromycin on the osteogenic function of osteoblasts using osteoblast-like MC3T3-E1 cells. Cells were cultured in the presence of 0, 0.1, 1, and 10 mu g/mL azithromycin, and cell proliferation and alkaline phosphatase (ALPase) activity were determined. In vitro mineralized nodule formation was detected with alizarin red staining. The expression of collagenous and non-collagenous bone matrix protein was determined using real-time PCR or enzyme-linked immunosorbent assays. In cells cultured with 10 mu g/mL azithromycin, the ALPase activity and mineralized nodule formation decreased, while the type I collagen, bone sialoprotein, osteocalcin, and osteopontin mRNA expression as well as osteopontin and phosphorylated osteopontin levels increased. These results suggest that a high azithromycin concentration (10 mu g/mL) suppresses mineralized nodule formation by decreasing ALPase activity and increasing osteopontin production, whereas low concentrations (<= l.0 mu g/mL) have no effect on osteogenic function in osteoblastic MC3T3-E1 cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available